Free lookups: 0/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
0 of 3 free lookups remaining Upgrade
New search Medicine profile Roxithromycin

Clinical medicine profile

Roxithromycin

Macrolide antibiotic

POM
Evidence state Source-linked Review date not recorded
Route
ORAL / IV (agent-dependent)
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • Hypersensitivity to macrolides.
  • Clarithromycin/erythromycin: concomitant strong CYP3A4 substrates with narrow therapeutic index where interaction is labelled contraindicated (e.g. certain ergot alkaloids, some statins — check SmPC).
  • History of cholestatic jaundice/hepatic dysfunction with prior macrolide.

Precautions

  • QT prolongation risk — caution with other QT drugs, electrolyte disturbance, cardiac disease.
  • Hepatic impairment.
  • Superinfection.
  • Myasthenia gravis may worsen.
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

Adults: 150mg BD or 300mg OD. Chil- dren: 2-5years; 5mg/kg BD. Taken on an empty stomach.

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

Usually less critical than beta-lactams; still review SmPC for severe impairment.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

Hepatotoxicity recognised (especially erythromycin estolate historically); monitor if prolonged therapy or prior liver disease.

03 Clinical use

Use, effects & interactions

Indications

  • E.N.T infections [mild to moderate], skin and soft tissues infections, gut infections.
  • Clinical selection for Roxithromycin should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
  • Class context: Macrolide antibiotic.
  • Confirm site-specific dose, duration and monitoring before prescribing.

Adverse effects

  • GI cramps, nausea, diarrhoea (erythromycin more prokinetic).
  • Taste disturbance (clarithromycin).
  • Serious: QT prolongation, hepatotoxicity, C. difficile, severe skin reactions (rare).
  • First-line for many atypical pneumonias and selected STIs.
  • Review drug–drug interactions before clarithromycin.
  • Resistance rising in streptococci/pneumococci in many regions — know local data.
04 Pharmacology

Mechanism & disposition

Binds to 50s sub-unit of the bacterial ribosome and inhibits bacterial protein synthesis by preventing attachment of aminoacyl transfer RNA to its acceptor site on the ribosome.

Bind ribosomeInhibit protein synthesisBacteriostatic / cidal
Read complete mechanism

Binds to 50s sub-unit of the bacterial ribosome and inhibits bacterial protein synthesis by preventing attachment of aminoacyl transfer RNA to its acceptor site on the ribosome. This prevents peptide bond formation by peptidyl transferase.

Onset

2–3 hours

Duration

12–24 h+ (azithromycin long tissue half-life)

Route

ORAL / IV (agent-dependent)

Distribution

and long terminal

Metabolism

(CYP3A4) with important interaction potential. Biliary

Elimination

important for some agents.

05 Special populations

Pregnancy, lactation & diet

Pregnancy

Often used when indicated (e.g. azithromycin in some STIs/pregnancy protocols); confirm local guidance.

Lactation

Usually compatible with monitoring; check agent-specific advice.

06 Kenya market

Brands & loaded prices

From
Median
Listings0
BrandManufacturerPackObserved price
No reviewed brand listings are linked yet.
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; RxNorm (NLM RxNav); PubChem; Professional class pharmacology (Macrolide antibiotic)
Last reviewedNot recorded
EvidenceSource-linked
Open source document ↗

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.